Thus, an interesting strategy to pursue to keep the HIPK2/p53 axis functioning in cancer patients affected by diabetes or by other pathologies with hyperglycemia could be to reduce the glycemic load, although this hypothesis needs to be supported by further studies for clinical application. Here, HIPK2 is linked to Hyperglycemia.